Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump [Yahoo! Finance]
Celldex Therapeutics, Inc. (CLDX)
Last celldex therapeutics, inc. earnings: 11/12 08:01 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.celldex.com
Company Research
Source: Yahoo! Finance
If you are wondering whether Celldex Therapeutics at around US$33.29 is still offering value or starting to look stretched, the key is understanding what the current price actually reflects. The stock has been volatile in the short term, with a 3.6% decline over the last week, a 5.1% return over the past month, and a 23.3% return year to date, while the 1 year return sits at 70.1%. Recent attention on Celldex has centered on its role in the biotech space and investor interest in companies pursuing new treatments, which often brings sharp shifts in sentiment. This context helps explain why the share price can move quickly as the market reassesses the potential of its pipeline and funding position. Right now, Celldex carries a valuation score of 3 out of 6 . The next sections will walk through how different valuation approaches interpret that score, and then finish with a framework that can help you make more sense of the numbers in the bigger picture. Celldex Therapeutics deli
Show less
Read more
Impact Snapshot
Event Time:
CLDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLDX alerts
High impacting Celldex Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CLDX
News
- Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.MarketBeat
- Celldex to Present at Upcoming Investor ConferenceGlobeNewswire
- Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Is Celldex's US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? [Yahoo! Finance]Yahoo! Finance
- Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch [Seeking Alpha]Seeking Alpha
CLDX
Earnings
- 2/25/26 - Miss
CLDX
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/29/26 - Form ARS
- 4/29/26 - Form DEF
- CLDX's page on the SEC website